2′-O-(2-methoxyethyl) nucleosides are not phosphorylated or incorporated into the genome of Human Lymphoblastoid TK6 Cells

OTS

Toxicology

February 28, 2018

SHARE

Post Views: 369

Looking for something?

Saleh AF, Bachman M, Priestley CC, Gooderham NJ, Andersson P, Henry SP, Edmunds N, Fellows MD.
Toxicol Sci. 2018 Jan 9.

Related articles

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma
April 23rd, 2021
Sequence-specific 2′-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

Sequence-specific 2′-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates
March 15th, 2021
Safety, Pharmacokinetic and Pharmacodynamic Evaluation of a 2′-MOE Antisense Oligonucleotide-GalNAc3 Conjugate that Targets the Human Transmembrane Protease Serine 6 (TMPRSS6)

Safety, Pharmacokinetic and Pharmacodynamic Evaluation of a 2′-MOE Antisense Oligonucleotide-GalNAc3 Conjugate that Targets the Human Transmembrane Protease Serine 6 (TMPRSS6)
February 16th, 2021
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data
January 30th, 2021
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease

Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
January 30th, 2021
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
December 23rd, 2020

Subscribe to our Newsletter

Oligonucleotide Therapeutics Society

Oligonucleotide Therapeutics Society

c/o Event Innovations, Inc.
4377 Newport Avenue
San Diego, CA 92107, USA

(619) 795-9458
info@oligotherapeutics.org

Terms & Conditions

Resources

Stay Connected

Search

Subscribe in a reader

© Copyright 2012 – 2022 | Oligotherapeutics.org | All Rights Reserved | Finfrock Marketing

Username/Email Address:
Password:
Forgot Password | Sign Up

Save Password

First Name *
Last Name *
Username *
Email *
Password *
Confirm Password *
Phone:
Organization Name
Select Sectors

By clicking checkbox, you agree to our Terms and Conditions and Privacy Policy

Already have an account? Login

This website uses cookies and third party services. Ok